JCI Insight (Sep 2023)

A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis

  • Giuseppina Augimeri,
  • Maria E. Gonzalez,
  • Alessandro Paolì,
  • Ahmad Eido,
  • Yehyun Choi,
  • Boris Burman,
  • Sabra Djomehri,
  • Santhosh Kumar Karthikeyan,
  • Sooryanarayana Varambally,
  • Johanna M. Buschhaus,
  • Yu-Chih Chen,
  • Loredana Mauro,
  • Daniela Bonofiglio,
  • Alexey I. Nesvizhskii,
  • Gary D. Luker,
  • Sebastiano Andò,
  • Euisik Yoon,
  • Celina G. Kleer

Journal volume & issue
Vol. 8, no. 18

Abstract

Read online

Patients with triple-negative breast cancer remain at risk for metastatic disease despite treatment. The acquisition of chemoresistance is a major cause of tumor relapse and death, but the mechanisms are far from understood. We have demonstrated that breast cancer cells (BCCs) can engulf mesenchymal stem/stromal cells (MSCs), leading to enhanced dissemination. Here, we show that clinical samples of primary invasive carcinoma and chemoresistant breast cancer metastasis contain a unique hybrid cancer cell population coexpressing pancytokeratin and the MSC marker fibroblast activation protein-α. We show that hybrid cells form in primary tumors and that they promote breast cancer metastasis and chemoresistance. Using single-cell microfluidics and in vivo models, we found that there are polyploid senescent cells within the hybrid cell population that contribute to metastatic dissemination. Our data reveal that Wnt Family Member 5A (WNT5A) plays a crucial role in supporting the chemoresistance properties of hybrid cells. Furthermore, we identified that WNT5A mediates hybrid cell formation through a phagocytosis-like mechanism that requires BCC-derived IL-6 and MSC-derived C-C Motif Chemokine Ligand 2. These findings reveal hybrid cell formation as a mechanism of chemoresistance and suggest that interrupting this mechanism may be a strategy in overcoming breast cancer drug resistance.

Keywords